Related Experiment Video

Updated: Mar 19, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Selective growth inhibition by suppression of F1Fo ATPase in canine malignant melanoma cell lines

S Kuroki1, M Kobayashi1, H Tani1

  • 1Department of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.

Journal of Veterinary Pharmacology and Therapeutics
|June 14, 2016
PubMed

Insights

Researchers screened compounds to find treatments for canine malignant melanoma (CMM). Oligomycin, an F1Fo ATPase inhibitor, showed potent growth inhibition in CMM cells, suggesting F1Fo ATPase as a potential therapeutic target for some CMM cases.

Area of Science:

  • Veterinary Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Canine malignant melanoma (CMM) is an aggressive cancer with limited treatment options.
  • Identifying novel therapeutic targets is crucial for improving outcomes in CMM patients.

Purpose of the Study:

  • To screen a chemical library for compounds inhibiting CMM cell growth.
  • To evaluate the therapeutic potential of identified compounds, specifically F1Fo ATPase inhibitors.

Main Methods:

  • Screening of 320 compounds for growth inhibitory activity against a CMM cell line (CMM-1).
  • Assessing the efficacy and toxicity of oligomycin A in multiple CMM cell lines and a control cell line (MDCK).
  • Measuring cellular ATP levels to understand the mechanism of action.

Main Results:

  • Oligomycin demonstrated potent growth inhibition in CMM-1 cells with lower toxicity in control cells.
  • Three out of six CMM lines were highly sensitive to oligomycin A, showing significantly lower IC50 values.
  • Sensitive CMM cells exhibited greater reductions in cellular ATP levels upon oligomycin A treatment.

Conclusions:

  • F1Fo ATPase is a potential therapeutic target in a subset of canine malignant melanoma.
  • While oligomycin itself has clinical limitations due to toxicity, targeting F1Fo ATPase warrants further investigation for CMM treatment.

More Related Videos

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

14.2K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K